Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2012 1
2014 1
2015 1
2016 2
2017 2
2018 1
2019 3
2020 3
2021 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab-induced adrenalitis.
Iqbal I, Khan MAA, Ullah W, Nabwani D. Iqbal I, et al. BMJ Case Rep. 2019 Dec 1;12(11):e231829. doi: 10.1136/bcr-2019-231829. BMJ Case Rep. 2019. PMID: 31791986 Free PMC article.
Here, we report a case of a 65-year-old woman with recurrent lung adenocarcinoma who was treated with nivolumab and developed immune-related adrenalitis, which was managed with hydrocortisone and fludrocortisone. ...
Here, we report a case of a 65-year-old woman with recurrent lung adenocarcinoma who was treated with nivolumab and dev …
Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report.
Ikeuchi K, Okuma Y, Tabata T. Ikeuchi K, et al. Lung Cancer. 2016 Sep;99:148-50. doi: 10.1016/j.lungcan.2016.07.001. Epub 2016 Jul 5. Lung Cancer. 2016. PMID: 27565931
However, less frequent irAEs may result in complications. Here, we report a patient with recurrent lung adenocarcinoma who was treated with nivolumab and developed immune-related pancreatitis. A 66-year-old Japanese female with recurrent lung …
However, less frequent irAEs may result in complications. Here, we report a patient with recurrent lung adenocarcinoma …
Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma.
Dimou A, Barron G, Merrick DT, Kolfenbach J, Doebele RC. Dimou A, et al. BMC Cancer. 2020 Mar 4;20(1):177. doi: 10.1186/s12885-020-6661-6. BMC Cancer. 2020. PMID: 32131760 Free PMC article.
CASE PRESENTATION: A 57 years old female patient was diagnosed with recurrent lung adenocarcinoma following initial lobectomy for early stage disease. A BRAF V600E mutation was identified at the time of recurrence and she received combination dabrafenib and t …
CASE PRESENTATION: A 57 years old female patient was diagnosed with recurrent lung adenocarcinoma following initial lob …
Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib.
Ren X, Cai X, Li J, Zhang X, Yu J, Song X, Zhang H, Song X. Ren X, et al. J Int Med Res. 2020 Jun;48(6):300060520927918. doi: 10.1177/0300060520927918. J Int Med Res. 2020. PMID: 32600081 Free PMC article.
We report a rare case of acquired resistance to osimertinib associated with transformation to small cell lung cancer (SCLC) with cis-C797S mutation. A man with recurrent lung adenocarcinoma harboring an EGFR exon 19 deletion received erlotinib for 10 months f …
We report a rare case of acquired resistance to osimertinib associated with transformation to small cell lung cancer (SCLC) with cis-C797S m …
Comparison of endostatin combined with PT-DC versus bevacizumab combined with PT-DC in the first-line treatment of advanced lung adenocarcinoma: a retrospective propensity score-matched cohort study.
Chen X, Nie J, Dai L, Hu W, Zhang J, Han J, Ma X, Tian G, Han S, Wu D, Wang Y, Long J, Zhang Z, Fang J. Chen X, et al. Ann Palliat Med. 2021 Jul;10(7):7847-7856. doi: 10.21037/apm-21-1401. Ann Palliat Med. 2021. PMID: 34353072 Free article.
METHODS: This retrospective cohort study examined the clinical data of patients with metastatic or recurrent lung adenocarcinoma (LUAD) treated with endostatin or bevacizumab combined with PT-DC as the first-line treatment from October 2010 to November …
METHODS: This retrospective cohort study examined the clinical data of patients with metastatic or recurrent lung ad …
Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report.
Maeda A, Nakata M, Shimizu K, Yukawa T, Saisho S, Okita R. Maeda A, et al. World J Surg Oncol. 2016 Jun 29;14(1):175. doi: 10.1186/s12957-016-0926-1. World J Surg Oncol. 2016. PMID: 27495256 Free PMC article.
CASE PRESENTATION: An 80-year-old woman who had been diagnosed with recurrent lung adenocarcinoma presented with remarkable appetite loss, abdominal distension, and constipation after starting gefitinib therapy. ...
CASE PRESENTATION: An 80-year-old woman who had been diagnosed with recurrent lung adenocarcinoma presented with remark …
An 81-Year-Old Man With Shortness of Breath After Chemotherapy and Radiation Therapy for Lung Cancer.
Mehta AK, Khan Z, Deepak J. Mehta AK, et al. Chest. 2019 Sep;156(3):e63-e67. doi: 10.1016/j.chest.2019.04.091. Chest. 2019. PMID: 31511162
He had been a longstanding tobacco smoker but quit two decades ago. Treatment of his recurrent lung adenocarcinoma included four cycles of carboplatin-pemetrexed over the preceding 5 months and intensity-modulated radiation therapy totaling 60 Gy over 30 frac …
He had been a longstanding tobacco smoker but quit two decades ago. Treatment of his recurrent lung adenocarcinoma incl …
The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.
Shoji F, Yano T, Yoshino I, Mori D, Yamasaki F, Kohno H, Maehara Y. Shoji F, et al. Eur J Surg Oncol. 2008 Jan;34(1):89-93. doi: 10.1016/j.ejso.2007.03.005. Epub 2007 Apr 20. Eur J Surg Oncol. 2008. PMID: 17449217
We reviewed postoperatively recurrent NSCLC patients who received gefitinib treatment, and analyzed both the clinical features and manifestations of treatment failure in patients who initially responded to gefitinib. METHODS: From 2002 to 2006, gefitinib was administered t …
We reviewed postoperatively recurrent NSCLC patients who received gefitinib treatment, and analyzed both the clinical features and ma …
New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib.
Zheng Y, Fang W, Liu X, Xu N. Zheng Y, et al. Tumori. 2012 Jul-Aug;98(4):e102-4. doi: 10.1177/030089161209800422. Tumori. 2012. PMID: 23052173
Icotinib is a new oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). We report on a 49-year-old man with recurrent lung adenocarcinoma treated with icotinib. The patient obtained a partial remission in 4 weeks that was maintained 14 …
Icotinib is a new oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). We report on a 49-year-old man with recur …
Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study.
Kim IA, Lee JS, Kim HJ, Kim WS, Lee KY. Kim IA, et al. BMC Cancer. 2018 Jul 28;18(1):768. doi: 10.1186/s12885-018-4691-0. BMC Cancer. 2018. PMID: 30055587 Free PMC article.
We aimed to investigate the effect of cumulative smoking dose(CSD) on clinical outcomes, including progression-free survival (PFS) and overall survival (OS), in patients with EGFR-mutated lung adenocarcinoma receiving EGFR-tyrosine kinase inhibitors (TKIs). METHODS: We ret …
We aimed to investigate the effect of cumulative smoking dose(CSD) on clinical outcomes, including progression-free survival (PFS) an …
16 results